Clinical trial
Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of…
NCT00240266 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00240266 |
|---|---|
| Title | Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT) |
| Official title | A Randomised, Double-blind, Placebo-controlled, Crossover Pilot Study to Define the High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT) |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metabolic Syndrome, Dyslipidemia |
| Intervention type | Drug |
| Interventions | Rosuvastatin |
| Enrollment | 15 |
| Start date | Aug 1, 2003 |
| Primary completion | Nov 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Oct 18, 2005 |
| Last update posted | Nov 19, 2010 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: